HIV cohort study comparing people on and off treatment
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This study follows adults with HIV over time to compare different groups based on how stable their virus levels are. It may help researchers understand who can safely interrupt treatment and who should stay on it, and how immune health changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have HIV-1 (not HIV-2).
- You can sign written consent and agree to follow study rules.
- You are covered by French Social Security.
- You are not currently on HIV antiretroviral therapy if you’re in the stable “ALT” or “HIC” groups.
- For the “PTC” group: your viral load was high (>2000 copies/mL) before starting treatment, you started within early infection or later infection, and after stopping treatment your viral load stayed below 400 copies/mL for 12 months (with a small allowance for one brief “blip”).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why some people with HIV on antiretroviral therapy still have small amounts of virus in their blood, while others achieve undetectable levels. Researchers will compare the two groups to understand the virus and immune system, which may help improve future treatments.
This study looks for markers in the blood that help some people with HIV stay virus-free without medication for a long time. If you have controlled your HIV without drugs for at least 6 months, or are interested in pausing your medication to see if you can control the virus, this study may help guide future treatments.
This study looks at how the immune system and HIV behave in people on long-term HIV treatment (ART), using blood samples that will be stored for future tests for up to 20 years. It may help researchers understand how well treatment is controlling HIV and improve future care.
This study looks at how certain immune cells (NK cells) behave in people who have been on HIV treatment for a long time. It aims to understand why some people's immune systems respond differently, which could help improve future treatments.
This study looks at people with HIV who have already taken a break from their HIV medications (called an analytic treatment interruption, or ATI) as part of another study. It aims to understand how well the body can control the virus during longer breaks from treatment, up to 96 weeks.
This is an observational study (not a new drug) that tracks how living with HIV can change over time in different treatment situations. It may help researchers understand long-term effects of the modern “protease inhibitor era” and improve future care.
Hear when a new HIV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.